Select Page

With several promising COVID-19 vaccines on the cusp of emergency use authorization, a top-5 pharmaceutical company sought competitive intelligence to guide clinical, commercial and access plans.

Working with a cross-functional team facing urgent timelines, Shift Health mined available evidence and engaged with global thought leaders to examine the technical and clinical merits, supply and deployment feasibility and access and adoption potential of competitor vaccines. We presented results and facilitated discussions with global and regional teams to align the organization on the differentiating aspects of their COVID-19 vaccine candidate and likely market scenarios that commercial and access teams will face upon launch.

Our findings equipped global and regional teams with a common understanding of the landscape and the key technical, logistical and market insights that will influence clinical, commercial and access planning.

Shift Health has provided the precedent-setting, entrepreneurial framework to enable strategy development and align international stakeholders on important global public health matters.


DR. JIM TARTAGLIA VP R&D, Sanofi Pasteur